Rapid Micro Biosystems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rapid Micro Biosystems announced equity inducement grants to a new employee on June 2, 2025.

Rhea-AI Summary

Rapid Micro Biosystems announced equity inducement grants to a new employee on June 2, 2025. The grants include 160,000 restricted stock units (RSUs) of Class A common stock and options to purchase 250,000 shares. The stock options have an exercise price of $3.45 per share, equal to the closing price on the grant date. The options will vest 25% after one year, followed by monthly vesting of 1/48th thereafter. RSUs will vest annually over three years, with one-third vesting each year. These grants were made under the Company's Inducement Plan and approved in accordance with Nasdaq Listing Rule 5635(c)(4), specifically designed for new employee incentives.

Positive

• Structured equity compensation plan to attract and retain key talent
• Alignment of employee interests with shareholders through stock-based compensation

Negative

• Potential dilution of existing shareholders from new equity grants
• Additional stock-based compensation expense impact on financial statements

Argus Session date unavailable

-1.41% session move Open Argus

Details

News Market Reaction – RPID

The recorded move for RPID in the trading session of this news was -1.41%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

LEXINGTON, Mass., June 13, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced the grants on June 2, 2025, of (i) 160,000 restricted stock units (“RSUs”) of the Company’s Class A common stock (“Common Stock”) and (ii) non-qualified stock options to purchase an aggregate of 250,000 shares of Common Stock (the “Options”) as a material inducement to employment to a new employee. All such equity awards were made under the Company’s Inducement Plan, as amended (the “Inducement Plan”) and were approved by a majority of the independent directors of the Board of Directors or a duly authorized committee thereof in accordance with Nasdaq Listing Rule 5635(c)(4). The equity awards are subject to the terms and conditions of the Inducement Plan, and the terms and conditions of the applicable stock option and RSU award agreements covering the grants.

The Options have an exercise price of $3.45 per share, which is equal to the closing price of Common Stock on their grant date. Twenty-five percent (25%) of Options will vest and become exercisable on the first anniversary of their grant date, and 1/48th of Options will vest and become exercisable each month thereafter, in each case, subject to such employee's continued employment on each vesting date.

The RSUs will vest annually over a three-year period, with one-third of the RSUs vesting on each anniversary of their grant date, subject to such employee's continued employment on each vesting date.

The Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of the Company, or following a bona fide period of non-employment, as an inducement material to such individual's entering into employment with the Company, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.

About Rapid Micro Biosystems

Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company’s flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (“MQC”) testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct system brings the quality control lab to the manufacturing floor, unlocking the power of MQC automation to deliver the faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered Lexington, Massachusetts and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Switzerland, Germany, and the Netherlands. For more information, please visit www.rapidmicrobio.com or follow the Company on X (formerly known as Twitter) at @rapidmicrobio or on LinkedIn. 

Investor Contact:
Michael Beaulieu, CFA
Vice President, Investor Relations and Corporate Communications
mbeaulieu@rapidmicrobio.com

Media Contact:
media@rapidmicrobio.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity grants did Rapid Micro Biosystems (RPID) announce on June 13, 2025?

Rapid Micro Biosystems announced grants of 160,000 RSUs and options to purchase 250,000 shares of Class A common stock at $3.45 per share to a new employee.

What is the vesting schedule for RPID's new equity grants?

The stock options vest 25% after one year with 1/48th monthly thereafter, while RSUs vest annually over three years with one-third vesting each year.

What is the purpose of RPID's Inducement Plan?

The Inducement Plan is exclusively used to grant equity awards to new employees as an inducement for joining the company, in compliance with Nasdaq Rule 5635(c)(4).

What is the exercise price for the stock options granted by RPID?

The stock options were granted with an exercise price of $3.45 per share, equal to the closing price of the common stock on the grant date of June 2, 2025.